Table 1.
Characteristics of the SARS-CoV-2 variants of interest and concern.
| PANGO Lineage | B.1.525 | B.1.526 | B.1.526.1 | B.1.617 | B.1.617.1 | B.1.617.3 | P.2 | B.1.1.7 | B.1.351 | B.1.427 | B.1.429 | B.1.617.2 | P.1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Classification | VOI | VOI | VOI | VOI | VOI | VOI | VOI | VOC | VOC | VOC | VOC | VOC | VOC |
| WHO label | Eta | Iota | - | - | Kappa | - | Zeta | Alpha | Beta | Epsilon | Epsilon | Delta | Gamma |
| Nextstrain name | 20A/S:484K | 20C/S:484K | 20C | 20A | 20A/S:154K | 20A | 20J | 20I/501Y.V1 | 20H/501.V2 | 20C/S:452R | 20C/S:452R | 20A/S:478K | 20J/501Y.V3 |
| First detected | UK/Nigeria | NY | NY | India | India | India | Brazil | UK | South Africa | CA | CA | India | Japan / Brazil |
| No. of spike mutations | 8 | 3–7 | 6–8 | 3 | 7–8 | 7 | 3–4 | 10–13 | 10 | 4 | 4 | 9–10 | 11 |
| RBD mutations | E484K | (S477N*) (E484K*) |
L452R | L452R E484Q |
L452R E484Q |
L452R E484Q | E484K | N501Y | K417N E484K N501Y |
L452R | L452R | L452R T478K |
K417T E484K N501Y |
| Other spike mutations | A67V, 69del, 70del, 144del, D614G, Q677H, F888L | (L5F*), T95I, D253G, D614G, (A701V*) | D80G, 144del, F157S, D614G, (T791I*), (T859N*), D950H | D614G | (T95I*), G142D, E154K, D614G, P681R, Q1071H | T19R, G142D, D614G, P681R, D950N | (F565L*), D614G, V1176F | 69del, 70del, 144del, (E484K*), (S494P*), A570D, D614G, P681H, T716I, S982A, D1118H (K1191N*) | D80A, D215G, 241del, 242del, 243del, D614G, A701V | S13I, W152C, D614G | S13I, W152C, D614G | T19R, (G142D*), 156del, 157del, R158G, D614G, P681R, D950N | L18F, T20N, P26S, D138Y, R190S, D614G, H655Y, T1027I |
| Transmission | - | - | - | - | - | - | - | 50% increased | 50% increased | 20% increased | 20% increased | Increased | - |
| Neutralization by convalescent and vaccine sera | Potential reduced | Reduced | Potential reduced | Slightly reduceda | Potential reduceda | Potential reduceda | Reduceda | Minimal impact | Reduced | Reduced | Reduced | Potential reduceda | Reduced |
| Neutralization by some EUA monoclonal antibody treatments | Potential reduced | Reducedb | Potential reduced | Potential reduced | Potential reduced | Potential reduced | Potential reduced | No Impact | Significant decreaseb | Modest decreaseb | Modest decreaseb | Potential reduced | Significant decreaseb |
Abbreviations: WHO, World Health Organization; EUA, Emergency Use Authorization; CA, California; NY, New York; RBD, receptor-binding domain; UK, United Kingdom; VOC, variant of concern; VOI, variant of interest.
This table is reproduced from data available on CDC website [88].
(*) means found in some sequences but not all.
aThe reported reductions in B.1.617, B.1.617.1, B.1.617.2, B.1.617.3, and P.2 are for neutralization by vaccine sera. No data for convalescent sera.
bThis reduction in susceptibility to the bamlanivimab and etesevimab monoclonal antibody combination treatment, however, other monoclonal antibody treatments are available.